• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Aptamer Extends Collaboration with AstraZeneca

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark

    Reed-Lane Facility Virtual Tour
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Data Management Trends

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Aptamer Extends Collaboration with AstraZeneca
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Cytovance Biologics

    Syngene

    PCI Pharma Services

    Reed-Lane

    Almac Group
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Cytovance Biologics

    Baxter BioPharma Solutions

    PCI Pharma Services

    Almac Group

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    Advancing Digital Endpoints in Clinical Trials

    An end-to-end approach to managing wearable devices through clinical development.

    Advancing Digital Endpoints in Clinical Trials
    Related CONTENT
    • Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions
    • Application of ICP-OES/ICP-MS in Pharmaceutical Analysis
    • 20th Annual Contracting & Outsourcing Conference & Exhibition
    • Virtual Clinical Trials: The Future of Dermatology Studies
    • Container Closure Integrity and Stability Testing for Rigid Containers
    Kristin Brooks, Contract Pharma12.14.20

    With the adoption of digital health technologies, sponsors, CROs, and other stakeholders are discovering how technologies such as wearable devices can enable patient-centric measurement of health markers and that frequent and continuous monitoring beyond the clinic can offer more precise and accurate assessments than traditional observational models.

    However, the lack of clear regulatory guidelines and standardization has limited the use of digital health technologies to generate endpoints in clinical research.

    Marie McCarthy, Senior Director of Product Innovation at ICON plc and Manpreet Sidhu, Executive Principal and Global Head of ICON’s Health Economics and Outcomes Research practice, discuss some of the lingering challenges the industry faces with widespread adoption of digital health technology, the data that can be leveraged from wearables, and where advances are being made. –KB
     

    Contract Pharma: What are some of the lingering challenges the industry faces with widespread adoption of digital health technology?

    Marie McCarthy: In an increasingly digital world, data is abundant, vast, and complex. These factors make collection, management and analysis challenging. The volume and diversity of data is contributing to concerns about high levels of delays and inefficiencies. Additional challenges include patient acceptance, privacy and security issues, and regulatory acceptance. In a recent webinar hosted by ICON, 40 percent of participants reported that regulatory authorities are the biggest barrier to the adoption of digital endpoints as there is no formal guidance with respect to the use of digital endpoints in a studies, though the FDA’s guidance (2009) on PRO endpoints can be used as a foundation. The lack of clear guidelines and standardization across countries and regions has led to cautious use of digital health technologies to generate digital endpoints in clinical research.

    In addition, even though digital devices can be used in clinical trials, it does not necessarily mean they should be. Sponsors need to take the patient's voice into consideration when deciding on study objectives by selecting digital endpoints that are meaningful to patients. Then, once the appropriate digital endpoint is identified, sponsors can consider the type of wearable or sensor that can provide meaningful data. In some instances, endpoints may be focused on assessing improvement in everyday function, while in others, it will be about measuring stability or deterioration in a condition.

    CP: Where are advances being made?

    MM: We’ve begun to witness some of the benefits of incorporating digital health technologies during the COVID-19 pandemic. The acceleration of their adoption is a combination of factors, including the growing availability of suitable technology and the increased adoption of these devices as part of standard care, in addition to telehealth visits and advice from regulators with respect to virtual visits. The FDA COVID-19-related guidance documents for clinical studies speaks to the evaluation of alternative methods, such virtual visits where in-person visits are no longer feasible.

    However, the use and adoption in drug development clinical trials is still in its infancy, partially due to a lack of definitive regulatory guidance. There are some collaborations such as the Clinical Trials Transformation initiatives (CTTI) which include members from industry, regulators and patients that have developed guidance documents for those interested in using devices in clinical trials. This includes:

    ●      Prioritize the patient - Sponsors should select measures with the patient in mind and capture insights that are not only clinically meaningful but are meaningful the patient

    ●      Select the device - The process of device selection involves device identification, patient acceptance testing, and technical usability and feasibility testing.

    ●      Manage operational excellence - Overlooking operational excellence can severely jeopardize the endpoint. Therefore, sponsors will need to look at the end-to-end process holistically and implement risk contingency, including logistics, data management, patient engagement, compliance and sites.

    CP: What are the regulatory hurdles around HTAs?

    Manpreet Sidhu: The requirements for global Health Technology Assessment (HTA)/reimbursement considerations are continuing to evolve in response to the current pandemic. HTA boards in most countries initially slowed or delayed their appraisal timelines during the early days of the pandemic, although most are now ‘back in business’, even if operating virtually. Also, some HTA boards have stated that they plan to prioritize certain products for appraisal before others. While very few of these bodies have been explicit about their criteria for prioritization, we can glean something from those that have.

    The National Institute for Health and Care Excellence (NICE) in the UK, the Dental and Pharmaceutical Benefits Agency (TLV) in Sweden, and Haute Autorité de santé (HAS) in France are all fast-tracking assessment of products related to COVID-19. Additionally, HAS has clarified that it will prioritize interventions in oncology, pediatrics or any medication in a serious disease with unmet need, and products for temporary use and requests for early care funding. It is also likely to evaluate indication extensions according to a simplified procedure.

    CP: How are HTAs being used in response to the pandemic?

    MS: As we come to the close of 2020, there is a significant push for approvals of vaccines and antivirals as governments begin to open up economies while preparing for future waves. Moving forward, we predict that HTA bodies will pivot, in the short term, toward assessing the evidence of antibodies, antivirals and vaccines. There will also be a clear focus on therapies that can free up resources that are in short supply, such as ICU (intensive care unit) beds and ventilators.

    For sponsors with products in classes that can be fast tracked, there should be a focus on demonstrating value within mainstream and unusual scenarios. For products in classes that are currently deprioritized, sponsors should use this time to fill data gaps with real-world data (RWD), expert opinions, and indirect treatment comparisons that will strengthen their case when the time comes. This will be especially important as health systems will have been depleted of financial resources and potentially will need to apply more stringent assessments.

    In view of the current pandemic and the impact on national health care budgets, as well as the economy globally and at a country level, the assessment of therapies to ensure ascertainment of value for the health care setting, and the patient, will continue to be a focus for authorities, therefore the requirement for evidence to support this value should be prioritized.

    CP: What data can be leveraged from wearables, and is it considered reliable?

    MM: There is increased interest in the use and value of digital endpoints in clinical studies, as illustrated by the FDA’s agreement to use a physical activity endpoint (MVPA) measured by an acitgraphy device as the primary endpoint in a pivotal Phase 3 cardiovascular study. 

    There is also a growing array of devices available to researchers. While the Apple Watch, Fitbit or Galaxy Watch3 were not initially developed for research use, they can still produce useful information with respect to an individual’s physical behaviors as they go about their daily lives. Increasingly, these devices are gaining credibility among the scientific community and are being used in clinical studies to track changes in physical activity and sleep patterns. Engagement by these companies with the FDA Precertification (Pre Cert) program has helped affirm their suitability as research tools. For these companies it is likely that FDA clearance of their electrocardiogram application, designed to detect signs of atrial fibrillation (AFib), has strengthened this credibility.

    The incorporation of photoplethysmography (ppg) sensors along with the standard accelerometers in these wearables is transforming them from mere fitness trackers into biosensors with the capability of measuring a large number of physiological parameters including blood oxygenation – an important parameter for respiratory diseases, including Covid-19.

    As the adoption of wearables grows, more sponsors, CROs, and other stakeholders are demonstrating how digital health technologies can enable patient-centric measurement of health markers, such as physical activity, sleep, heart rate, medication adherence and respiration patterns/rate. Frequent and continuous monitoring — beyond the walls of the clinic — can offer more precise and accurate assessments than traditional observational models.

    Further, digital health technologies can capture new measurements that would have been unimaginable previously. For example, a team at Johns Hopkins conducted an observational study requiring subjects to perform five cognitive tasks on a smartphone application, then merged the task data to form a validated mobile Parkinson’s disease (PD) score. Using a novel machine-learning approach, they demonstrated how this score complements standard PD measures by providing frequent, objective, real-world assessments that could enhance the clinical care and evaluation of therapeutics.


    Marie McCarthy is part of the multidisciplinary Innovation Team at ICON plc. Seen as a key Entrepreneur within the organization she has specific responsibility for developing solutions in the direct to patient paradigm. Her focus is primarily on the use of wearables and sensors in clinical trials, with particular emphasis on the potential these devices have to monitor the physical behaviors of the digital patient. Prior to ICON, Marie was EU Sales and Marketing Manager with Philips Respironics, building awareness of the value of Actigraphy endpoints among Clinicians and Researchers.

    Manpreet Sidhu has over 20 years of experience in health economics, including strategic evidence generation planning, project management, systematic reviews, economic modeling, strategic market access, and dossier development.  She leads ICON’s Health Economics and Outcomes Research practice which delivers innovative tailored solutions to help clients generate HEOR evidence, meet specific HTA challenges with early advice and submissions, support market access and bolster arguments for product reimbursement.

    Related Searches
    • Clinical Trials
    • Drug Development
    • Information Technology
    Suggested For You
    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions
    Application of ICP-OES/ICP-MS in Pharmaceutical Analysis Application of ICP-OES/ICP-MS in Pharmaceutical Analysis
    20th Annual Contracting & Outsourcing Conference & Exhibition 20th Annual Contracting & Outsourcing Conference & Exhibition
    Virtual Clinical Trials: The Future of Dermatology Studies Virtual Clinical Trials: The Future of Dermatology Studies
    Container Closure Integrity and Stability Testing for Rigid Containers Container Closure Integrity and Stability Testing for Rigid Containers
    Pharmaceutical and Biotherapeutic Development and Testing Pharmaceutical and Biotherapeutic Development and Testing
    Drug Product Development, Manufacturing, and Packaging Drug Product Development, Manufacturing, and Packaging
    The Changing R&D Landscape The Changing R&D Landscape
    Structural Characterization of Biologics Using High-Resolution Mass Spectrometry Structural Characterization of Biologics Using High-Resolution Mass Spectrometry
    RTP Formulation & Sterile Fill-Finish Facility RTP Formulation & Sterile Fill-Finish Facility
    Beyond Elemental Impurities: New Applications of ICP-MS Beyond Elemental Impurities: New Applications of ICP-MS
    [VIRTUAL LAUNCH] Redefining Virus Manufacturing with NevoLine™ Upstream [VIRTUAL LAUNCH] Redefining Virus Manufacturing with NevoLine™ Upstream
    CPI Scales Up Manufacturing of Pyocin S5 CPI Scales Up Manufacturing of Pyocin S5
    Navigating Uncertainty: Considerations for Life Sciences 2021 Navigating Uncertainty: Considerations for Life Sciences 2021
    Thermo Fisher Scientific Further Expands Global Footprint Thermo Fisher Scientific Further Expands Global Footprint

    Related Online Exclusives

    • Biologics, Proteins, Vaccines | Clinical Trials
      Inside a Vaccine Trial

      Inside a Vaccine Trial

      Dr. Murphy of ICON, provider of clinical services to Pfizer/BioNTech’s COVID vaccine program, discusses what it takes to conduct a vaccine trial of this scale.
      Kristin Brooks, Managing Editor 02.05.21

    • Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development
      The Future of Vaccines and Biologics

      The Future of Vaccines and Biologics

      Dr. Linda Marbán of Capricor Therapeutics discusses the advances in responding to infectious diseases.
      Kristin Brooks, Managing Editor, Contract Pharma 02.04.21

    • Clinical Trials | Information Technology
      The State of Clinical Trial Technology

      The State of Clinical Trial Technology

      Blake Adams of Florence discusses key report findings and the clinical trial software used to support Pfizer’s global COVID-19 vaccine study.
      Kristin Brooks, Contract Pharma 01.26.21


    • Analytical Services | Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development | Fill/Finish
      A New Era of Vaccine and Biologic Drug Development

      A New Era of Vaccine and Biologic Drug Development

      As a result of COVID-19, unprecedented investments in vaccines, diagnostics, and treatments have had a tremendous impact on the Biotechnology industry.
      Kristin Brooks, Managing Editor 01.12.21

    • Drug Delivery | Drug Development
      Inhaled Drug Delivery Technology Trends

      Inhaled Drug Delivery Technology Trends

      The success of new inhaled medicines relies on the correct combination of formulation and device technology.
      Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 11.24.20

    • Bioanalytical Services | cGMP Manufacture | Drug Development | Scale-up/Technology Transfer
      CDMOs: Keeping up with Science & Technology

      CDMOs: Keeping up with Science & Technology

      Enhancing the development of increasingly advanced and complex drug candidates is needed to drive growth in the industry.
      Kristin Brooks, Contract Pharma 11.12.20


    • Clinical Trials | Drug Development | Preclinical Outsourcing
      Accelerating R&D Trends

      Accelerating R&D Trends

      The pandemic has propelled lingering trends into the forefront and increasingly complex molecules and biologics have drug developers outsourcing more.
      Kristin Brooks, Contract Pharma 10.20.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Contract Pharma 08.25.20

    • Drug Development | Information Technology
      Trade Secret Litigation: Vulnerabilities Within Pharma Amid Hacking Efforts

      Trade Secret Litigation: Vulnerabilities Within Pharma Amid Hacking Efforts

      Theft of IP belonging to companies developing biologics and other drugs, including COVID-19 treatments and vaccines, poses a threat to innovation.
      Kristin Brooks, Contract Pharma 08.19.20


    • Drug Development | Industry News
      Top Companies Report: Biogen

      Top Companies Report: Biogen

      Expands pipeline of disease-modifying therapies for Alzheimer’s and Parkinson’s, adds gene therapies focused on AAV treatments, bolsters biosimilars portfolio.
      Kristin Brooks, Contract Pharma 07.10.20

    • Analytical Services | Biologics, Proteins, Vaccines | Drug Development | Drug Discovery | Laboratory Testing
      A Shifting Drug Development Landscape Amid COVID-19 Crisis

      A Shifting Drug Development Landscape Amid COVID-19 Crisis

      Responding to demand for challenging assays and custom solutions required for complex molecules, biologics, vaccines and other innovative therapies.
      Kristin Brooks, Contract Pharma 06.22.20

    • Drug Development | Information Technology
      Advancing AI Initiatives in R&D

      Advancing AI Initiatives in R&D

      Richard Lee of ACD/Labs discusses the possibilities of using AI in R&D, and what this outlook means for IT leaders at pharmaceutical organizations.
      Kristin Brooks, Contract Pharma 06.11.20


    • Clinical Trials
      Impact of COVID-19 on Winning New Business

      Impact of COVID-19 on Winning New Business

      WuXi Clinical’s Vice President of Biometrics, David Ng, talks about the impact of COVID-19 on clinical trials and business relations
      Tim Wright, Editor, Contract Pharma 06.03.20

    • APIs | cGMP Manufacture | Clinical Trials | Supply Chain
      Evaluating Pharma Amid COVID-19

      Evaluating Pharma Amid COVID-19

      Dr. Ural of Ernst & Young LLP discusses market dynamics, enduring therapeutic areas, near term M&A, and how industry can use this time for transformation
      Kristin Brooks, Contract Pharma 05.18.20

    • Clinical Trials
      Pioneering Medicine Forward

      Pioneering Medicine Forward

      May 20th marks Clinical Trials Day, celebrating 273 years of clinical trials
      Tina Bland, Senior Consultant, KCR Trial Execution Consulting 05.18.20

    Trending
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • Reed-Lane Facility Virtual Tour
    Breaking News
    • AGC Biologics Expands Cell and Gene Facility in Italy
    • Celonic to Boost Cell & Gene Therapy Production
    • Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    • Aptamer Extends Collaboration with AstraZeneca
    • Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Thymoquinone Inhibits Viral Infection in In Vitro Settings, New Study Finds
    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Coatings World

    Latest Breaking News From Coatings World

    Sherwin-Williams Announces Resignation of President, COO
    Ashland Completes Expansion, Relocation of Viatel Bioresorbable Polymers Manufacturing Facility
    Evonik Receives Sustainability Award from EcoVadis
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex CFO Announces Retirement
    New AI-Based Tool Developed for Coronary Artery Analysis, Intervention Planning
    First Reported Use of Pulse Biosciences' CellFX System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    AGC Biologics Expands Cell and Gene Facility in Italy
    Celonic to Boost Cell & Gene Therapy Production
    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Ulta Beauty Opens in Herald Square
    Elizabeth Arden Taps Sui He as Global Brand Ambassador
    Natura &Co Outperforms the Global Market in Q4 2020
    Happi

    Latest Breaking News From Happi

    What You're Reading on Happi.com
    Indie Beauty Innovators Wanted
    Cosmetic Chemists Seek Mentors
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Arjobex America welcomes Maggie Naberezny to sales team
    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Colfax Decides to Divide Its Businesses
    Stryker Corp.'s 2020 Sales Slip 3.6 Percent
    Bioventus Appoints Managing Director, China and Asia Pacific
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login